Rigel Pharmaceuticals Inc (STU:RI2A)
€ 0.878 0.002 (0.24%) Market Cap: 157.65 Mil Enterprise Value: 167.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Rigel Pharmaceuticals Inc Investor and Analyst Call Transcript

Oct 23, 2019 / 02:00PM GMT
Release Date Price: €1.54 (+3.36%)
Operator

Greeting and welcome to Rigel Pharmaceuticals' Investor and Analyst Conference Call (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. Thank you, Ms. Vance, you may begin.

Dolly A. Vance
Rigel Pharmaceuticals, Inc. - Executive VP of Corporate Affairs, General Counsel & Corporate Secretary

Welcome to Rigel's Investor and Analyst Conference Call. We have posted the accompanying presentation for today's call in the Event section on our Investor Relations page on our website at www.rigel.com. As a reminder, during today's call, we may make forward-looking statements. These statements are subject to risks and uncertainties that may cause the actual results to differ from those forecasted. A discussion of these risks can be found in our most recent quarterly report on Form 10-Q on file with the SEC. Any forward-looking statements are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot